Champions Oncology Inc (CSBR) Posts Quarterly Earnings Results
Champions Oncology Inc (OTCMKTS:CSBR) released its earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. Champions Oncology had a negative return on equity of 796.94% and a negative net margin of 65.16%. The business had revenue of $5.03 million for the quarter.
Shares of Champions Oncology (OTCMKTS CSBR) traded up 9.01% during trading on Friday, reaching $3.51. The company had a trading volume of 54,121 shares. The company’s market capitalization is $38.55 million. The stock’s 50-day moving average price is $3.09 and its 200-day moving average price is $2.83. Champions Oncology has a 52 week low of $1.48 and a 52 week high of $4.79.
Separately, ValuEngine upgraded Champions Oncology from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd.
An institutional investor recently raised its position in Champions Oncology stock. GRT Capital Partners L.L.C. lifted its holdings in Champions Oncology Inc (OTCMKTS:CSBR) by 70.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,064 shares of the biotechnology company’s stock after purchasing an additional 17,000 shares during the period. GRT Capital Partners L.L.C. owned about 0.37% of Champions Oncology worth $106,000 as of its most recent filing with the Securities & Exchange Commission.
ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/15/champions-oncology-inc-csbr-posts-quarterly-earnings-results.html.
Champions Oncology Company Profile
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.